These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24552476)

  • 1. Adherence to TNF-alpha inhibitors in patients with hidradenitis suppurativa.
    Thomsen SF; Sand FL
    J Dermatolog Treat; 2015 Feb; 26(1):97-8. PubMed ID: 24552476
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of Treatment With TNF-α Inhibitors for Hidradenitis Suppurativa During the COVID-19 Pandemic.
    Benesh G; Andriano TM; Babbush KM; Hosgood HD; Cohen SR
    J Cutan Med Surg; 2021; 25(4):446-448. PubMed ID: 33625899
    [No Abstract]   [Full Text] [Related]  

  • 3. Antitumour necrosis factor-α therapy for hidradenitis suppurativa: results from a national cohort study between 2000 and 2013.
    Sbidian E; Hotz C; Seneschal J; Maruani A; Amelot F; Aubin F; Paul C; Beylot Barry M; Humbert P; Dupuy A; Caux F; Dupin N; Modiano P; Lepesant P; Ingen-Housz-Oro S; Mahé E; Bachelez H; Chosidow O; Wolkenstein P
    Br J Dermatol; 2016 Mar; 174(3):667-70. PubMed ID: 26406350
    [No Abstract]   [Full Text] [Related]  

  • 4. Rotational therapy with TNF-alpha blockers for recalcitrant hidradenitis suppurativa.
    Brunasso AM; Massone C
    Eur J Dermatol; 2010; 20(5):644-6. PubMed ID: 20615818
    [No Abstract]   [Full Text] [Related]  

  • 5. Hidradenitis suppurativa: are tumour necrosis factor-alpha blockers the ultimate alternative?
    Brunasso AM; Delfino C; Massone C
    Br J Dermatol; 2008 Sep; 159(3):761-3. PubMed ID: 18627370
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-TNF-α therapy modulates mTORC1 signalling in hidradenitis suppurativa.
    Balato A; Caiazzo G; Annunziata MC; Marasca C; Scala E; Cacciapuoti S; Fabbrocini G
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):e43-e45. PubMed ID: 29956847
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors: An update on infliximab.
    Brunasso AM; Massone C
    Acta Derm Venereol; 2011 Jan; 91(1):70-1. PubMed ID: 21103830
    [No Abstract]   [Full Text] [Related]  

  • 8. Update on TNF Inhibitors in Dermatology.
    Sobell JM
    Semin Cutan Med Surg; 2016 Jun; 35(6 Suppl):S104-6. PubMed ID: 27537073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor necrosis factor (TNF)-induced lupus in a patient with hidradenitis suppurativa.
    Turk D; Vellaichamy G; Lyons AB; Parks-Miller A; Nelson T; Meysami A; Hamzavi IH
    Int J Dermatol; 2020 Mar; 59(3):e73-e74. PubMed ID: 31633193
    [No Abstract]   [Full Text] [Related]  

  • 10. Etanercept for the treatment of hidradenitis suppurativa.
    Sotiriou E; Apalla Z; Ioannidos D
    Acta Derm Venereol; 2009; 89(1):82-3. PubMed ID: 19197548
    [No Abstract]   [Full Text] [Related]  

  • 11. Moderate to severe hidradenitis suppurativa treated with biological therapies.
    Chinniah N; Cains GD
    Australas J Dermatol; 2014 May; 55(2):128-31. PubMed ID: 24456051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Summaries for patients. Adalimumab for the treatment of hidradenitis suppurativa.
    Ann Intern Med; 2012 Dec; 157(12):I-50. PubMed ID: 23247950
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of moderate to severe hidradenitis suppurativa.
    Kimball AB; Gu Y; Okun M
    Ann Intern Med; 2013 Jul; 159(1):72-3. PubMed ID: 23817710
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of moderate to severe hidradenitis suppurativa.
    Prasad V
    Ann Intern Med; 2013 Jul; 159(1):72. PubMed ID: 23817709
    [No Abstract]   [Full Text] [Related]  

  • 15. Flexural or inverse psoriasis in a patient with hidradenitis suppurativa receiving treatment with infliximab.
    Nuño-González A; Dehesa L; Ricotti C; Kerdel F
    Actas Dermosifiliogr; 2012 Dec; 103(10):936-7. PubMed ID: 23149048
    [No Abstract]   [Full Text] [Related]  

  • 16. Sirolimus as combination rescue therapy with tumor necrosis alpha inhibitors for severe, refractory hidradenitis suppurativa.
    Bettuzzi T; Frumholtz L; Jachiet M; Lepelletier C; Djermane M; Cordoliani F; Saussine A; Bouaziz JD; Bachelez H
    J Am Acad Dermatol; 2020 Nov; 83(5):1441-1444. PubMed ID: 32565204
    [No Abstract]   [Full Text] [Related]  

  • 17. PsAPASH: a new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition.
    Saraceno R; Babino G; Chiricozzi A; Zangrilli A; Chimenti S
    J Am Acad Dermatol; 2015 Jan; 72(1):e42-4. PubMed ID: 25497954
    [No Abstract]   [Full Text] [Related]  

  • 18. Low prescription of tumor necrosis alpha inhibitors in hidradenitis suppurativa: A cross-sectional analysis.
    Orenstein LAV; Wright S; Strunk A; Garg A
    J Am Acad Dermatol; 2021 May; 84(5):1399-1401. PubMed ID: 32758630
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a real-life experience.
    Bettoli V; Manfredini M; Calamo G; Forconi R; Bencivelli D; Mantovani L; Pellacani G; Corazza M
    Dermatol Ther; 2018 Nov; 31(6):e12737. PubMed ID: 30295378
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment options in severe hidradenitis suppurativa].
    Mooij JE; van't Oost L; Leenarts MF; Mekkes JR
    Ned Tijdschr Geneeskd; 2011; 155():A1912. PubMed ID: 21426594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.